<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has shared an update. Guangzhou Baiyunshan Pharmaceutical Holdings has announced that the term of its ninth board is ending and that shareholders will vote on a new, tenth board at the 2025 annual general meeting. The proposed board will comprise eleven directors, including ten non‑employee representatives and one employee representative elected separately by staff. The company has nominated ten director candidates, combining reappointments of existing executive and independent non‑executive directors with several new nominees. It emphasized that candidates meet Hong Kong listing rules on independence and disclosure, and, if approved, each director will serve a three‑year term, underscoring a focus on governance continuity and regulatory compliance. More about Guangzhou Baiyunshan Pharmaceutical Holdings Company Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a Chinese joint stock company listed in Hong Kong that operates in the pharmaceutical industry. The group focuses on manufacturing and distributing medicines and related healthcare products, serving domestic and international markets through its diversified portfolio and established brands. Average Trading Volume: 1,261,587 Technical Sentiment Signal: Sell Current Market Cap: HK$40.41B For a thorough assessment of 0874 stock, go to TipRanks’ Stock Analysis page.</div>

00874

159849

513120

Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) announced that its ninth board's term is ending, and shareholders will vote on a new tenth board at the 2025 annual general meeting. The proposed board will consist of eleven directors, including ten non-employee representatives and one employee representative. The company has nominated ten candidates, focusing on governance continuity and compliance with Hong Kong listing rules. If approved, each director will serve a three-year term. The company operates in the pharmaceutical industry, manufacturing and distributing medicines and healthcare products.

Tip Ranks

BAIYUNSHAN PH

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Southern Hang Seng Biotech ETF(QDII)

China Universal 800 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Penghua CSI HK Connect Health Care Composite ETF

Huaan Hang Seng Biotech ETF

GYBYS

Guangzhou Baiyunshan Pharma Sets Vote on New Three-Year Board Line-Up